Reversal of tumor immunosuppression and induction of potent antitumor immunity via albumin-based co-delivery of paclitaxel and a PD-L1 inhibitor

Key Points

• Enhanced antitumor immunity was achieved via co-delivery system.
• Combination therapy with paclitaxel and PD-L1 inhibitor shows a remarkable 70% reduction in tumor growth in preclinical models.
• Analysis employed a co-delivery strategy leveraging albumin to improve drug efficacy and reduce immunosuppression.
• Findings suggest this method could inform future cancer treatment approaches, with potential clinical applications pending.